Join to View Full Profile
1695 Eastchester Rd2nd floorBronx, NY 10461
Phone+1 718-405-8505
Fax+1 718-405-8433
Dr. Anampa Mesias is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a breast medical oncologist with a strong interest in new therapeutic approaches and immune therapies for breast cancer. My goal is to help patients who are affected with breast diseases and provide the state of art treatment for them. In addition to my clinical practice, I participate in clinical/translational research, and I am also an educator for future oncology physicians.
Education & Training
Albert Einstein college of MedicineMS, Clinical research, MS with Distintion, 2016 - 2018
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2011 - 2014- Rochester General HospitalResidency, Internal Medicine, 2008 - 2011
Cayetano Heredia UniversityClass of 2006
Certifications & Licensure
NY State Medical License 2014 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- CDK and Body Composition Study Start of enrollment: 2019 Jan 08
Roles: Principal Investigator
Publications & Presentations
PubMed
- Racial disparities in treatment and outcomes between Hispanic and non-Hispanic black women with triple-negative breast cancer.Jesus D Anampa, Alvaro Alvarez Soto, Ana M Bernal, Ana Acuna-Villaorduna
Breast Cancer Research and Treatment. 2025-04-01 - The association between allostatic load and lymphedema in breast cancer survivors.Barnabas Obeng-Gyasi, Yevgeniya Gokun, Mohamed I Elsaid, J C Chen, Barbara L Andersen
Supportive Care in Cancer. 2025-03-21 - 1 citationsPhase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer.Jesus D Anampa, Daniel L Flynn, Cynthia Leary, Sun Oh, Xiaonan Xue
Clinical Cancer Research. 2025-01-17
Press Mentions
By the Numbers: Monthly Treatment Cost Not Tied to Survival in Breast CancerSeptember 26th, 2024
Professional Memberships
- Member
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
